The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian
Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study

J 2024

The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study

PRESL, Jiri; Pavel HAVELKA; Vít WEINBERGER; Petra OVESNÁ; Peter FEKETE et. al.

Basic information

Original name

The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study

Authors

PRESL, Jiri (203 Czech Republic); Pavel HAVELKA (203 Czech Republic); Vít WEINBERGER (203 Czech Republic, belonging to the institution); Petra OVESNÁ (203 Czech Republic, belonging to the institution); Peter FEKETE (203 Czech Republic); Filip FRUHAUF (203 Czech Republic); Marcin JEDRYKA; Branislav BYSTRICKY (203 Czech Republic); Aleksandra STROJNA; Nataliya VOLODKO; Olga MATYLEVICH; Petra HERBOLTOVA (203 Czech Republic); Pawel BLECHARZ; Vladimir KALIST; Lucie EHRLICHOVÁ (203 Czech Republic, belonging to the institution); Petr STRANIK (203 Czech Republic); Ladislav MASAK (203 Czech Republic); Renata PONCOVA (203 Czech Republic); Andrzej CZEKANSKI; Barbora CHALOUPKOVA (203 Czech Republic); Michaela KOBLIZKOVA (203 Czech Republic); Vendula SMOLIGOVA (203 Czech Republic); Marketa HRABALOVA (203 Czech Republic); Alena JAKSICOVA (203 Czech Republic); Peter LINKESCH (203 Czech Republic); Libor VIKTORA (203 Czech Republic); Jiri BOUDA (203 Czech Republic); Pavel VLASAK (203 Czech Republic) and Jan KOSTUN (203 Czech Republic)

Edition

Cancers, BASEL, MDPI, 2024, 2072-6694

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 4.400

RIV identification code

RIV/00216224:14110/24:00137803

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.3390/cancers16213566

UT WoS

001351050500001

EID Scopus

2-s2.0-85208401807

Keywords in English

ovarian cancer; tumor markers; CA125; HE4; recurrence detection

Abstract

In the original language

Background: Ovarian, fallopian tube, and primary peritoneal cancers often share clinical characteristics and are typically diagnosed at advanced stages due to nonspecific symptoms. The utility of tumor markers, particularly CA125 and HE4, in the diagnosis and follow-up of these cancers remains an area of active investigation. Objectives: The CEEGOG (Central and Eastern European Gynecologic Oncology Group) OX-01 study aimed to evaluate HE4's role alongside CA125 in follow-up for advanced-stage ovarian, fallopian tube, and primary peritoneal cancers. It assessed the potential for detecting recurrence using marker elevation and imaging methods, examining the necessity of dynamic monitoring and current cut-off values' accuracy for early relapse detection. Methods: In this multicenter prospective cohort study, 117 eligible patients with Stage III-IV cancers were included. Patients had elevated CA125 or HE4 at diagnosis and achieved complete remission after first-line treatment. HE4 and CA125 levels were monitored every 3-4 months in the first two years and every six months thereafter. CT scans were performed if markers exceeded set thresholds or increased by over 20%. Results: During a median follow-up of 13.7 months, 73% of patients relapsed. Median HE4 levels were significantly higher in relapsed patients. A 10 IU/mL increase from baseline in CA125 had a sensitivity of 83% and specificity of 93%, while a 15 pmol/L increase in HE4 had a sensitivity of 74% and specificity of 92% for predicting relapse up to three months before CT scan detection. Conclusions: The study found that dynamic changes in HE4 and CA125 levels, rather than predefined cut-off values, are crucial for early relapse detection. These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.

Cite

PRESL, Jiri; Pavel HAVELKA; Vít WEINBERGER; Petra OVESNÁ; Peter FEKETE; Filip FRUHAUF; Marcin JEDRYKA; Branislav BYSTRICKY; Aleksandra STROJNA; Nataliya VOLODKO; Olga MATYLEVICH; Petra HERBOLTOVA; Pawel BLECHARZ; Vladimir KALIST; Lucie EHRLICHOVÁ; Petr STRANIK; Ladislav MASAK; Renata PONCOVA; Andrzej CZEKANSKI; Barbora CHALOUPKOVA; Michaela KOBLIZKOVA; Vendula SMOLIGOVA; Marketa HRABALOVA; Alena JAKSICOVA; Peter LINKESCH; Libor VIKTORA; Jiri BOUDA; Pavel VLASAK and Jan KOSTUN. The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study. Cancers. BASEL: MDPI, 2024, vol. 16, No 21, p. 1-12. ISSN 2072-6694. Available from: https://doi.org/10.3390/cancers16213566.

@article{2455462,
   author = {Presl, Jiri and Havelka, Pavel and Weinberger, Vít and Ovesná, Petra and Fekete, Peter and Fruhauf, Filip and Jedryka, Marcin and Bystricky, Branislav and Strojna, Aleksandra and Volodko, Nataliya and Matylevich, Olga and Herboltova, Petra and Blecharz, Pawel and Kalist, Vladimir and Ehrlichová, Lucie and Stranik, Petr and Masak, Ladislav and Poncova, Renata and Czekanski, Andrzej and Chaloupkova, Barbora and Koblizkova, Michaela and Smoligova, Vendula and Hrabalova, Marketa and Jaksicova, Alena and Linkesch, Peter and Viktora, Libor and Bouda, Jiri and Vlasak, Pavel and Kostun, Jan},
   article_location = {BASEL},
   article_number = {21},
   doi = {https://doi.org/10.3390/cancers16213566},
   keywords = {ovarian cancer; tumor markers; CA125; HE4; recurrence detection},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study},
   url = {https://www.mdpi.com/2072-6694/16/21/3566},
   volume = {16},
   year = {2024}
}

TY  - JOUR
ID  - 2455462
AU  - Presl, Jiri - Havelka, Pavel - Weinberger, Vít - Ovesná, Petra - Fekete, Peter - Fruhauf, Filip - Jedryka, Marcin - Bystricky, Branislav - Strojna, Aleksandra - Volodko, Nataliya - Matylevich, Olga - Herboltova, Petra - Blecharz, Pawel - Kalist, Vladimir - Ehrlichová, Lucie - Stranik, Petr - Masak, Ladislav - Poncova, Renata - Czekanski, Andrzej - Chaloupkova, Barbora - Koblizkova, Michaela - Smoligova, Vendula - Hrabalova, Marketa - Jaksicova, Alena - Linkesch, Peter - Viktora, Libor - Bouda, Jiri - Vlasak, Pavel - Kostun, Jan
PY  - 2024
TI  - The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study
JF  - Cancers
VL  - 16
IS  - 21
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20726694
KW  - ovarian cancer
KW  - tumor markers
KW  - CA125
KW  - HE4
KW  - recurrence detection
UR  - https://www.mdpi.com/2072-6694/16/21/3566
N2  - Background: Ovarian, fallopian tube, and primary peritoneal cancers often share clinical characteristics and are typically diagnosed at advanced stages due to nonspecific symptoms. The utility of tumor markers, particularly CA125 and HE4, in the diagnosis and follow-up of these cancers remains an area of active investigation. Objectives: The CEEGOG (Central and Eastern European Gynecologic Oncology Group) OX-01 study aimed to evaluate HE4's role alongside CA125 in follow-up for advanced-stage ovarian, fallopian tube, and primary peritoneal cancers. It assessed the potential for detecting recurrence using marker elevation and imaging methods, examining the necessity of dynamic monitoring and current cut-off values' accuracy for early relapse detection. Methods: In this multicenter prospective cohort study, 117 eligible patients with Stage III-IV cancers were included. Patients had elevated CA125 or HE4 at diagnosis and achieved complete remission after first-line treatment. HE4 and CA125 levels were monitored every 3-4 months in the first two years and every six months thereafter. CT scans were performed if markers exceeded set thresholds or increased by over 20%. Results: During a median follow-up of 13.7 months, 73% of patients relapsed. Median HE4 levels were significantly higher in relapsed patients. A 10 IU/mL increase from baseline in CA125 had a sensitivity of 83% and specificity of 93%, while a 15 pmol/L increase in HE4 had a sensitivity of 74% and specificity of 92% for predicting relapse up to three months before CT scan detection. Conclusions: The study found that dynamic changes in HE4 and CA125 levels, rather than predefined cut-off values, are crucial for early relapse detection. These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.
ER  -

PRESL, Jiri; Pavel HAVELKA; Vít WEINBERGER; Petra OVESNÁ; Peter FEKETE; Filip FRUHAUF; Marcin JEDRYKA; Branislav BYSTRICKY; Aleksandra STROJNA; Nataliya VOLODKO; Olga MATYLEVICH; Petra HERBOLTOVA; Pawel BLECHARZ; Vladimir KALIST; Lucie EHRLICHOVÁ; Petr STRANIK; Ladislav MASAK; Renata PONCOVA; Andrzej CZEKANSKI; Barbora CHALOUPKOVA; Michaela KOBLIZKOVA; Vendula SMOLIGOVA; Marketa HRABALOVA; Alena JAKSICOVA; Peter LINKESCH; Libor VIKTORA; Jiri BOUDA; Pavel VLASAK and Jan KOSTUN. The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study. \textit{Cancers}. BASEL: MDPI, 2024, vol.~16, No~21, p.~1-12. ISSN~2072-6694. Available from: https://doi.org/10.3390/cancers16213566.

Přehled o publikaci